Cargando…
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Tumor necrosis factor-α (TNF-α) antagonists, the first biologics approved for treating patients with inflammatory bowel disease (IBD), are effective for the induction and maintenance of remission and significantly improving prognosis. However, up to one-third of treated patients show primary nonresp...
Autores principales: | Wang, Liang-Fang, Chen, Ping-Run, He, Si-Ke, Duan, Shi-Hao, Zhang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445007/ https://www.ncbi.nlm.nih.gov/pubmed/37621757 http://dx.doi.org/10.3748/wjg.v29.i29.4481 |
Ejemplares similares
-
Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring
por: Kumar, Peeyush, et al.
Publicado: (2023) -
Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013) -
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
por: Verstockt, Sare, et al.
Publicado: (2021) -
Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021) -
Nonresponse in household interview surveys
por: Groves, Robert M.
Publicado: (1998)